R01AI162815

Negative regulation of innate immune signaling pathways by the selective autophagy receptor TAX1BP1 - Abstract

Innate immunity provides the first line of host defense in response to invading pathogens. Pattern recognition receptors (PRRs) sense pathogen-associated molecular patterns (PAMPs) in viruses and other pathogens. RIG-I/MDA-5 are DExD/H box RNA helicases in the RIG-I-like receptor (RLR) pathway that detect double-stranded RNA viral genomes and activate the mitochondrial adaptor protein MAVS. The DNA sensor cGAS detects double-stranded DNA and activates STING, a transmembrane endoplasmic reticulum adaptor.

Both MAVS and STING activate canonical (IKKα and IKKβ), and noncanonical IKK kinases (TBK1 and IKKε) to activate transcription factors NF-κB and IRF3 respectively. Together, IRF3 and NF-κB regulate the expression of type I interferon (IFN) and inflammatory genes that coordinate the innate response and initiate the adaptive immune response against pathogens.

The NLRP3 inflammasome also plays a critical role in inflammatory responses by triggering caspase-1-mediated pro-IL-1β cleavage to yield the biologically active form of IL-1β that drives inflammation and adaptive immunity. NLRP3 also induces a highly lytic form of inflammatory cell death termed pyroptosis via cleavage of gasdermin-D to form plasma membrane pores.

The RLR, cGAS-STING, and NLRP3 inflammasome pathways are potent inducers of inflammation that must be tightly regulated to avert overexuberant inflammation and tissue damage.

TAX1BP1 was first identified as an anti-apoptotic protein that interacts with the zinc finger deubiquitinase A20/TNFAIP3. Our previous work has established that TAX1BP1 restricts cytokine-induced NF-κB activation as well as RLR-induced type I IFN production and apoptosis. TAX1BP1 functions as a selective autophagy receptor by recruiting ubiquitinated cargo to developing autophagosomes via two LC3 interaction regions (LIRs). However, it remains unclear how TAX1BP1 autophagy function is regulated and if TAX1BP1 inhibits other innate immune signaling pathways.

In preliminary studies, we provide experimental evidence that TAX1BP1 is phosphorylated by both noncanonical and canonical IKK kinases, which controls both basal and virus-induced TAX1BP1 autophagic degradation respectively. Using TAX1BP1-deficient macrophages, we have demonstrated that TAX1BP1 is a novel inhibitor of both cGAS-STING and NLRP3 pathways. Furthermore, MAVS protein aggregates accumulate in TAX1BP1-deficient cells, suggesting a potential aggrephagy function in the regulation of innate immune signaling.

The central hypothesis driving the proposed investigations is that TAX1BP1 inhibits RLR, cGAS-STING, and NLRP3 pathways by autophagy-mediated clearance of signaling protein aggregates. We will test this hypothesis experimentally with the following specific aims:

(1) Determine the role of TAX1BP1 phosphorylation in its autophagy function.
(2) Determine the mechanisms of TAX1BP1 inhibition of the cGAS-STING pathway.
(3) Determine the mechanisms of TAX1BP1 inhibition of the NLRP3 pathway.

Completion of the proposed studies will provide new insights into innate immune regulation and immune homeostasis.

Pennsylvania State University

TO ASSIST PUBLIC AND PRIVATE NONPROFIT INSTITUTIONS AND INDIVIDUALS TO ESTABLISH, EXPAND AND IMPROVE BIOMEDICAL RESEARCH AND RESEARCH TRAINING IN INFECTIOUS DISEASES AND RELATED AREAS, TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS. TO ASSIST PUBLIC, PRIVATE AND COMMERCIAL INSTITUTIONS TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS, TO PROVIDE RESEARCH SERVICES AS REQUIRED BY THE AGENCY FOR PROGRAMS IN INFECTIOUS DISEASES, AND CONTROLLING DISEASE CAUSED BY INFECTIOUS OR PARASITIC AGENTS, ALLERGIC AND IMMUNOLOGIC DISEASES AND RELATED AREAS. PROJECTS RANGE FROM STUDIES OF MICROBIAL PHYSIOLOGY AND ANTIGENIC STRUCTURE TO COLLABORATIVE TRIALS OF EXPERIMENTAL DRUGS AND VACCINES, MECHANISMS OF RESISTANCE TO ANTIBIOTICS AS WELL AS RESEARCH DEALING WITH EPIDEMIOLOGICAL OBSERVATIONS IN HOSPITALIZED PATIENTS OR COMMUNITY POPULATIONS AND PROGRESS IN ALLERGIC AND IMMUNOLOGIC DISEASES. BECAUSE OF THIS DUAL FOCUS, THE PROGRAM ENCOMPASSES BOTH BASIC RESEARCH AND CLINICAL RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM EXPANDS AND IMPROVES PRIVATE SECTOR PARTICIPATION IN BIOMEDICAL RESEARCH. THE SBIR PROGRAM INTENDS TO INCREASE AND FACILITATE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATES AND FOSTERS SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. RESEARCH CAREER DEVELOPMENT AWARDS SUPPORT THE DEVELOPMENT OF SCIENTISTS DURING THE FORMATIVE STAGES OF THEIR CAREERS. INDIVIDUAL NATIONAL RESEARCH SERVICE AWARDS (NRSAS) ARE MADE DIRECTLY TO APPROVE APPLICANTS FOR RESEARCH TRAINING IN SPECIFIED BIOMEDICAL SHORTAGE AREAS. IN ADDITION, INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDS ARE MADE TO ENABLE INSTITUTIONS TO SELECT AND MAKE AWARDS TO INDIVIDUALS TO RECEIVE TRAINING UNDER THE AEGIS OF THEIR INSTITUTIONAL PROGRAM.

93.855 - Allergy and Infectious Diseases Research

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

Hershey, Pennsylvania 170332360 United States

Single Zip Code

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)

Amendment Since initial award the total obligations have increased 412% from $642,863 to $3,291,455.